Massachusetts General Hospital logoPsychosis Consultation ServiceDepartment of Psychiatry
Back to what we provide

Treatment-resistant schizophrenia

Why Recognizing Treatment-Resistant Schizophrenia Matters

About one-third of people with schizophrenia have treatment-resistant schizophrenia. For many patients, treatment resistance is apparent early in the illness.

Recognizing it promptly is important because delaying effective treatment can allow symptoms and disability to accumulate—and may reduce the likelihood of responding well to clozapine later.

Continue to key points

Reasons recognizing treatment-resistant schizophrenia matters

  • Persistent psychosis can lead to worsening function.

    Ongoing symptoms can interfere with thinking, communication, self-care, relationships, school, work, and independent living. Repeated crises and hospitalizations can make it increasingly difficult to regain these parts of life.

  • Repeatedly trying similar medications may delay effective treatment.

    Once treatment resistance is established, switching from one non-clozapine antipsychotic to another may add side effects without adequately controlling the psychosis.

  • Clozapine is the only evidence-based medication specifically recommended for treatment-resistant schizophrenia.

    Longer delays before starting clozapine are associated with poorer symptom improvement, more hospitalizations, and a lower likelihood of responding well to clozapine.

  • A specialty consultation can clarify the next step.

    The evaluation can confirm whether treatment resistance is truly present, identify correctable reasons for poor response, and determine whether clozapine is appropriate and safe.

Evidence snapshot

Why early recognition and timely treatment matter

Up to 1 in 3
Across the course of schizophrenia, treatment resistance may affect up to one-third of patients, including people who become resistant after an initial response.[1]
70%
In one longitudinal first-episode cohort, 70% of treatment-resistant cases showed resistance from the onset of illness.[6]
81.6% vs. 30.8%
In one observational study, clozapine response was higher with a delay of 2.8 years or less than with a delay longer than 2.8 years.[5]

Estimates vary with the definition of treatment resistance and length of follow-up. The 70% finding comes from one longitudinal first-episode cohort. The clozapine comparison comes from a retrospective observational study and shows an association; it does not establish that delay alone caused the difference in response.

References

  1. Siskind D, Orr S, Sinha S, Yu O, Brijball B, Warren N, et al. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. Br J Psychiatry. 2022;220(3):115-20.
  2. Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJM, Birnbaum ML, et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis Working Group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174(3):216-29.
  3. Demjaha A, Lappin JM, Stahl D, Patel MX, MacCabe JH, Howes OD, et al. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med. 2017;47(11):1981-9.
  4. Shah P, Iwata Y, Plitman E, Brown EE, Caravaggio F, Kim J, et al. The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: a systematic review. Psychiatry Res. 2018;268:114-22.
  5. Yoshimura B, Yada Y, So R, Takaki M, Yamada N. The critical treatment window of clozapine in treatment-resistant schizophrenia: secondary analysis of an observational study. Psychiatry Res. 2017;250:65-70.
  6. Lally J, Ajnakina O, Di Forti M, Trotta A, Demjaha A, Kolliakou A, et al. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychol Med. 2016;46(15):3231-3240.